Skip to main content
SpringerLink
Log in

Anti-IgE Therapy: Clinical Utility and Mechanistic Insights

  • Chapter
  • First Online:
Book cover IgE Antibodies: Generation and Function

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 388))

Abstract

As the major trigger of acute allergic reactions, IgE has long been considered an ideal target for anti-allergy treatments. Omalizumab, first approved by the USA in 2003 and now in use in many other countries is a humanized monoclonal antibody that binds serum IgE. Anti-IgE therapy using omalizumab reduces circulating free IgE levels and blocks both early and late-phase reactions to allergen challenge. It has proven effective for allergic asthma and is currently being evaluated for use in a number of other atopic conditions including allergic rhinitis and chronic idiopathic urticaria. Clinical observations and mechanistic studies with omalizumab have shed new light on the multifaceted roles of IgE in immune homeostasis and in allergic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Acharya M, Borland G, Edkins AL, Maclellan LM, Matheson J, Ozanne BW, Cushley W (2010) CD23/Fc epsilon RII: molecular multi-tasking. Clin Exp Immunol 162(1):12–23. doi:10.1111/j.1365-2249.2010.04210.x

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa GD, Sandstrom T (2000) Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106(2):253–259. doi:10.1067/mai.2000.108310

    Article  CAS  PubMed  Google Scholar 

  • Asai K, Kitaura J, Kawakami Y, Yamagata N, Tsai M, Carbone DP, Liu FT, Galli SJ, Kawakami T (2001) Regulation of mast cell survival by IgE. Immunity 14(6):791–800

    Article  CAS  PubMed  Google Scholar 

  • Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S (2004) Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J Allergy Clin Immunol 114(3):527–530

    Article  CAS  PubMed  Google Scholar 

  • Borkowski TA, Jouvin MH, Lin SY, Kinet JP (2001) Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol 167(3):1290–1296

    Article  CAS  PubMed  Google Scholar 

  • Boulet LP, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, DeVault A, Fick RB Jr, Cockcroft DW (1997) Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155(6):1835–1840. doi:10.1164/ajrccm.155.6.9196083

    Article  CAS  PubMed  Google Scholar 

  • Boushey HA Jr (2001) Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 108(2 Suppl):S77–83

    Article  CAS  PubMed  Google Scholar 

  • Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, Nguyen A, Yeh S, Delarosa D, Leong SR, Wong T, Chen Y, Ultsch M, Luis E, Ramani SR, Jackman J, Gonzalez L, Dennis MS, Chuntharapai A, DeForge L, Meng YG, Xu M, Eigenbrot C, Lee WP, Refino CJ, Balazs M, Wu LC (2010) Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Investig 120(6):2218–2229. doi:10.1172/JCI40141

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108(2):184–190

    Article  CAS  PubMed  Google Scholar 

  • Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ, Sorkness CA (2011) Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364(11):1005–1015. doi:10.1056/NEJMoa1009705

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Cameron L, Gounni AS, Frenkiel S, Lavigne F, Vercelli D, Hamid Q (2003) S epsilon S mu and S epsilon S gamma switch circles in human nasal mucosa following ex vivo allergen challenge: evidence for direct as well as sequential class switch recombination. J Immunol 171(7):3816–3822

    Article  CAS  PubMed  Google Scholar 

  • Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB Jr, Adelman DC (1997) Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100(1):110–121

    Article  CAS  PubMed  Google Scholar 

  • Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Della Cioppa G (2001) Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 286(23):2956–2967

    Article  CAS  PubMed  Google Scholar 

  • Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117(1):134–140. doi:10.1016/j.jaci.2005.09.036

    Article  CAS  PubMed  Google Scholar 

  • Chang TW (2000) The pharmacological basis of anti-IgE therapy. Nat Biotechnol 18(2):157–162

    Article  CAS  PubMed  Google Scholar 

  • Chang TW, Wu PC, Hsu CL, Hung AF (2007) Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol 93:63–119. doi:10.1016/S0065-2776(06)93002-8

    Article  CAS  PubMed  Google Scholar 

  • Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, Shen H, Fox H (2003) Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 91(2):160–167. doi:10.1016/S1081-1206(10)62171-0

    Article  CAS  PubMed  Google Scholar 

  • Cohen ES, Dobson CL, Kack H, Wang B, Sims DA, Lloyd CO, England E, Rees DG, Guo H, Karagiannis SN, O’Brien S, Persdotter S, Ekdahl H, Butler R, Keyes F, Oakley S, Carlsson M, Briend E, Wilkinson T, Anderson IK, Monk PD, von Wachenfeldt K, Eriksson PO, Gould HJ, Vaughan TJ, May RD (2014) A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs 6(3):1

    Article  Google Scholar 

  • Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV (2004) Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170(6):583–593. doi:10.1164/rccm.200312-1651OC

    Article  PubMed  Google Scholar 

  • Dombrowicz D, Quatannens B, Papin JP, Capron A, Capron M (2000) Expression of a functional Fc epsilon RI on rat eosinophils and macrophages. J Immunol 165(3):1266–1271

    Article  CAS  PubMed  Google Scholar 

  • Durrani SR, Montville DJ, Pratt AS, Sahu S, DeVries MK, Rajamanickam V, Gangnon RE, Gill MA, Gern JE, Lemanske RF Jr, Jackson DJ (2012) Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol 130(2):489–495. doi:10.1016/j.jaci.2012.05.023

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Eckman JA, Sterba PM, Kelly D, Alexander V, Liu MC, Bochner BS, Macglashan DW Jr, Saini SS (2010) Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 125(4):889–895. doi:10.1016/j.jaci.2009.09.012 e887

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Eggel A, Baravalle G, Hobi G, Kim B, Buschor P, Forrer P, Shin JS, Vogel M, Stadler BM, Dahinden CA, Jardetzky TS (2014) Accelerated dissociation of IgE-Fc epsilon RI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol 133(6):1709–1719. doi:10.1016/j.jaci.2014.02.005

  • Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA (1997) The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155(6):1828–1834. doi:10.1164/ajrccm.155.6.9196082

    Article  CAS  PubMed  Google Scholar 

  • Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG, Metcalfe DD, Mannon PJ, Prussin C (2007) Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 120(3):594–601. doi:10.1016/j.jaci.2007.06.015

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB (1996) Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 279(2):1000–1008

    CAS  PubMed  Google Scholar 

  • Gill MA, Bajwa G, George TA, Dong CC, Dougherty II, Jiang N, Gan VN, Gruchalla RS (2010) Counterregulation between the Fc epsilon RI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 184(11):5999–6006. doi:10.4049/jimmunol.0901194

    Article  CAS  PubMed  Google Scholar 

  • Gould HJ, Sutton BJ (2008) IgE in allergy and asthma today. Nat Rev Immunol 8(3):205–217. doi:10.1038/nri2273

    Article  CAS  PubMed  Google Scholar 

  • Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L (2003) The biology of IGE and the basis of allergic disease. Annu Rev Immunol 21:579–628

    Article  CAS  PubMed  Google Scholar 

  • Grattan CE, Francis DM, Hide M, Greaves MW (1991) Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 21(6):695–704

    Article  CAS  PubMed  Google Scholar 

  • Grayson MH, Cheung D, Rohlfing MM, Kitchens R, Spiegel DE, Tucker J, Battaile JT, Alevy Y, Yan L, Agapov E, Kim EY, Holtzman MJ (2007) Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia. J Exp Med 204(11):2759–2769

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Haak-Frendscho M, Robbins K, Lyon R, Shields R, Hooley J, Schoenhoff M, Jardieu P (1994) Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunol 82(2):306–313

    CAS  Google Scholar 

  • Hanf G, Noga O, O’Connor A, Kunkel G (2004) Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J 23(3):414–418

    Article  CAS  PubMed  Google Scholar 

  • Heil PM, Maurer D, Klein B, Hultsch T, Stingl G (2010) Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course—a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 8(12):990–998. doi:10.1111/j.1610-0387.2010.07497.x

    PubMed  Google Scholar 

  • Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW (1993) Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 328(22):1599–1604. doi:10.1056/NEJM199306033282204

    Article  CAS  PubMed  Google Scholar 

  • Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E (2014) Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Des Devel Ther 8:197–207. doi:10.2147/DDDT.S49409

    Article  PubMed Central  PubMed  Google Scholar 

  • James LC, Roversi P, Tawfik DS (2003) Antibody multispecificity mediated by conformational diversity. Science 299(5611):1362–1367. doi:10.1126/science.1079731

    Article  CAS  PubMed  Google Scholar 

  • Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, Siraganian RP, Krystal G (2001) Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 14(6):801–811

    Article  CAS  PubMed  Google Scholar 

  • Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK (2008) Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 122(3):569–573. doi:10.1016/j.jaci.2008.07.006

    Article  CAS  PubMed  Google Scholar 

  • Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Staubach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosen K (2013) Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132(1):101–109. doi:10.1016/j.jaci.2013.05.013

    Article  CAS  PubMed  Google Scholar 

  • Kashiwakura J, Okayama Y, Furue M, Kabashima K, Shimada S, Ra C, Siraganian RP, Kawakami Y, Kawakami T (2012) Most highly cytokinergic IgEs have polyreactivity to autoantigens. Allergy Asthma Immunol Res 4(6):332–340. doi:10.4168/aair.2012.4.6.332

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kikuchi Y, Kaplan AP (2001) Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 107(6):1056–1062. doi:10.1067/mai.2001.115484

    Article  CAS  PubMed  Google Scholar 

  • Kisselgof AB, Oettgen HC (1998) The expression of murine B cell CD23, in vivo, is regulated by its ligand, IgE. Int Immunol 10(9):1377–1384

    Article  CAS  PubMed  Google Scholar 

  • Kraft S, Kinet JP (2007) New developments in Fc epsilon RI regulation, function and inhibition. Nat Rev Immunol 7(5):365–378. doi:10.1038/nri2072

    Article  CAS  PubMed  Google Scholar 

  • Kubo S, Nakayama T, Matsuoka K, Yonekawa H, Karasuyama H (2003) Long term maintenance of IgE-mediated memory in mast cells in the absence of detectable serum IgE. J Immunol 170(2):775–780

    Article  CAS  PubMed  Google Scholar 

  • Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Grave M, Hultsch T, Wahn U (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109(2):274–280

    Article  CAS  PubMed  Google Scholar 

  • Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF (2009) Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 124(6):1210–1216. doi:10.1016/j.jaci.2009.09.021

    Article  CAS  PubMed  Google Scholar 

  • Lemanske RF Jr, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N (2002) Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 110(5):e55

    Article  PubMed  Google Scholar 

  • Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR Jr (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348(11):986–993

    Article  CAS  PubMed  Google Scholar 

  • Lin S, Cicala C, Scharenberg AM, Kinet JP (1996) The Fc(epsilon)RI beta subunit functions as an amplifier of Fc(epsilon)RI gamma-mediated cell activation signals. Cell 85(7):985–995

    Article  CAS  PubMed  Google Scholar 

  • Liu J, Lester P, Builder S, Shire SJ (1995) Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34(33):10474–10482

    Article  CAS  PubMed  Google Scholar 

  • MacGlashan D Jr (2008) IgE receptor and signal transduction in mast cells and basophils. Curr Opin Immunol 20(6):717–723. doi:10.1016/j.coi.2008.08.004

    Article  CAS  PubMed  Google Scholar 

  • MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM (1997) Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158(3):1438–1445

    CAS  PubMed  Google Scholar 

  • Massanari M, Milgrom H, Pollard S, Maykut RJ, Kianifard F, Fowler-Taylor A, Geba GP, Zeldin RK (2009) Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate–severe allergic asthma. Clin Pediatr (Phila) 48(8):859–865. doi:10.1177/0009922809339054

    Article  CAS  Google Scholar 

  • Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, Zeldin RK (2010) Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125(2):383–389. doi:10.1016/j.jaci.2009.11.022

    Article  CAS  PubMed  Google Scholar 

  • Mathias CB, Freyschmidt EJ, Caplan B, Jones T, Poddighe D, Xing W, Harrison KL, Gurish MF, Oettgen HC (2009) IgE influences the number and function of mature mast cells, but not progenitor recruitment in allergic pulmonary inflammation. J Immunol 182(4):2416–2424. doi:10.4049/jimmunol.0801569 [pii] 182/4/2416

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Matsubara S, Li G, Takeda K, Loader JE, Pine P, Masuda ES, Miyahara N, Miyahara S, Lucas JJ, Dakhama A, Gelfand EW (2006) Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 173(1):56–63. doi:10.1164/rccm.200503-361OC

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368(10):924–935. doi:10.1056/NEJMoa1215372

    Article  CAS  PubMed  Google Scholar 

  • Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 study group. N Engl J Med 341(26):1966–1973

    Article  CAS  PubMed  Google Scholar 

  • Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108(2):E36

    Article  CAS  PubMed  Google Scholar 

  • Moy LY, Jia Y, Caniga M, Lieber G, Gil M, Fernandez X, Sirkowski E, Miller R, Alexander JP, Lee HH, Shin JD, Ellis JM, Chen H, Wilhelm A, Yu H, Vincent S, Chapman RW, Kelly N, Hickey E, Abraham WM, Northrup A, Miller T, Houshyar H, Crackower MA (2013) Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction. Am J Respir Cell Mol Biol 49(6):1085–1092. doi:10.1165/rcmb.2013-0200OC

    Article  CAS  PubMed  Google Scholar 

  • Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT (2011) Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 127(6):1622–1624. doi:10.1016/j.jaci.2011.04.009

    Article  PubMed Central  PubMed  Google Scholar 

  • Noga O, Hanf G, Kunkel G (2003) Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 131(1):46–52 doi: 70434

    Article  CAS  PubMed  Google Scholar 

  • Normansell R, Walker S, Milan SJ, Walters EH, Nair P (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 1:CD003559. doi:10.1002/14651858.CD003559.pub4

  • Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou TT, Ying S, Kay AB (2005) Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 116(3):558–564. doi:10.1016/j.jaci.2005.05.035

    Article  CAS  PubMed  Google Scholar 

  • Pelaia G, Gallelli L, Renda T, Romeo P, Busceti MT, Grembiale RD, Maselli R, Marsico SA, Vatrella A (2011) Update on optimal use of omalizumab in management of asthma. J Asthma Allergy 4:49–59. doi:10.2147/JAA.S14520

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Penton PC, Wang X, Amatullah H, Cooper J, Godri K, North ML, Khanna N, Scott JA, Chow CW (2013) Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma. J Allergy Clin Immunol 131(2):512–520. doi:10.1016/j.jaci.2012.07.039 e511-510

    Article  CAS  PubMed  Google Scholar 

  • Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, Gustafsson H, Sandstrom T, Rak S (2002) The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 110(1):68–71

    Article  CAS  PubMed  Google Scholar 

  • Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (1993) Humanization of an antibody directed against IgE. J Immunol 151(5):2623–2632

    CAS  PubMed  Google Scholar 

  • Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB (2003) Omalizumab treatment downregulates dendritic cell Fc epsilon RI expression. J Allergy Clin Immunol 112(6):1147–1154

    Article  CAS  PubMed  Google Scholar 

  • Saini SS, MacGlashan DW Jr, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, Bochner BS (1999) Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162(9):5624–5630

    CAS  PubMed  Google Scholar 

  • Saini SS, Klion AD, Holland SM, Hamilton RG, Bochner BS, Macglashan DW Jr (2000) The relationship between serum IgE and surface levels of Fc epsilon R on human leukocytes in various diseases: correlation of expression with Fc epsilon RI on basophils but not on monocytes or eosinophils. J Allergy Clin Immunol 106(3):514–520

    Article  CAS  PubMed  Google Scholar 

  • Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, Wong DA (2011) A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 127(5):1309–1310. doi:10.1016/j.jaci.2011.01.051 e1301

    Article  CAS  PubMed  Google Scholar 

  • Schneider LC, Rachid R, Lebovidge J, Blood E, Mittal M, Umetsu DT (2013) A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 132(6):1368–1374. doi:10.1016/j.jaci.2013.09.046

    Article  CAS  PubMed  Google Scholar 

  • Schroeder JT, Bieneman AP, Chichester KL, Hamilton RG, Xiao H, Saini SS, Liu MC (2010) Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 125(4):896–901. doi:10.1016/j.jaci.2009.10.021 e896

    Article  CAS  PubMed  Google Scholar 

  • Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB (2008) Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29(5):530–537. doi:10.2500/aap.2008.29.3160

    Article  CAS  PubMed  Google Scholar 

  • Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18(2):254–261

    Article  CAS  PubMed  Google Scholar 

  • Sutton BJ, Gould HJ (1993) The human IgE network. Nature 366(6454):421–428. doi:10.1038/366421a0

    Article  CAS  PubMed  Google Scholar 

  • Sykes A, Edwards MR, Macintyre J, del Rosario A, Bakhsoliani E, Trujillo-Torralbo MB, Kon OM, Mallia P, McHale M, Johnston SL (2012) Rhinovirus 16-induced IFN-alpha and IFN-beta are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol 129(6):1506–1514. doi:10.1016/j.jaci.2012.03.044 e1506

    Article  CAS  PubMed  Google Scholar 

  • Xiong H, Curotto de Lafaille MA, Lafaille JJ (2012) What is unique about the IgE response? Adv Immunol 116:113–141. doi:10.1016/B978-0-12-394300-2.00004-1

    Article  CAS  PubMed  Google Scholar 

  • Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, Kinet JP, Galli SJ (1997) IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 185(4):663–672

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Nakashima K, Ishimori M, Nagai H, Li YF, Yura T, Bacon KB (2003) The orally available spleen tyrosine kinase inhibitor 2-[7-(3, 4-dimethoxyphenyl)-imidazo[1, 2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 306(3):1174–1181. doi:10.1124/jpet.103.052316

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, 02115, USA

    Stephanie L. Logsdon & Hans C. Oettgen

Authors
  1. Stephanie L. Logsdon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans C. Oettgen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans C. Oettgen .

Editor information

Editors and Affiliations

  1. Skirball Institute and Department of Pathology, New York University School of Medicine, New York, USA

    Juan J. Lafaille

  2. Singapore Immunology Network (SIgN), Agency for Science, Technology and Research, Singapore, Singapore

    Maria A. Curotto de Lafaille

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Logsdon, S.L., Oettgen, H.C. (2015). Anti-IgE Therapy: Clinical Utility and Mechanistic Insights. In: Lafaille, J., Curotto de Lafaille, M. (eds) IgE Antibodies: Generation and Function. Current Topics in Microbiology and Immunology, vol 388. Springer, Cham. https://doi.org/10.1007/978-3-319-13725-4_3

Download citation

Publish with us

Policies and ethics

Search

Navigation